These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 22350917)

  • 1. PROTAC-induced proteolytic targeting.
    Carmony KC; Kim KB
    Methods Mol Biol; 2012; 832():627-38. PubMed ID: 22350917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
    Moon S; Lee BH
    Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in PROTACs for Drug Targeted Protein Research.
    Yao T; Xiao H; Wang H; Xu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
    Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
    Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTACs: Novel approach for cancer breakdown by breaking proteins.
    Memon H; Patel BM
    Life Sci; 2022 Jul; 300():120577. PubMed ID: 35487303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome substrate receptors and their therapeutic potential.
    Osei-Amponsa V; Walters KJ
    Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PROTAC technology in drug development.
    Zou Y; Ma D; Wang Y
    Cell Biochem Funct; 2019 Jan; 37(1):21-30. PubMed ID: 30604499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
    Rothweiler EM; Brennan PE; Huber KVM
    Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
    Burslem GM; Crews CM
    Cell; 2020 Apr; 181(1):102-114. PubMed ID: 31955850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin proteasome system in immune regulation and therapeutics.
    Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
    Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
    Liu Z; Liu S
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.